PHASE I/II STUDY OF VOSAROXIN AND DECITABINE IN NEWLY DIAGNOSED OLDER PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)

被引：0
|
作者：
Daver, N. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Jabbour, E. [1 ]
Borthakur, G. [1 ]
Pierce, S. [1 ]
Vaughan, K. [1 ]
Vaughan, K. [1 ]
Ning, J. [2 ]
Gonzalez, G. [2 ]
Pemmarjau, N. [1 ]
Kadia, T. [1 ]
Konopleva, M. [1 ]
Andreeff, M. [1 ]
DiNardo, C. [1 ]
Cortes, J. [1 ]
Ward, R. [3 ]
Craig, A. [3 ]
Ravandi, F. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Sunesis Inc, San Francisco, CA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S505
引用
收藏
页码：187 / 188
页数：2
相关论文
共 50 条
  • [31] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Reddy, E. Premkumar
    Holland, James F.
    Wilhelm, Francois
    Silverman, Lewis R.
    BLOOD, 2012, 120 (21)
  • [32] A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML)
    Maris, M. B.
    Ravandi, F.
    Stuart, R.
    Stone, R.
    Cripe, L.
    Cooper, M.
    Strickland, S.
    Turturro, F.
    Stock, W.
    Berman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Mistry, B.
    Gibiansky, L.
    Hussein, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] Prognostic factors associated with progression of myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) in patients (pts) treated with decitabine.
    Fullmer, A.
    Borthakur, G.
    Kadia, T. M.
    Garcia-Manero, G.
    Jabbour, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Fried's Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Taborda, Cristian C.
    Gier, Shannon H.
    Stivale, Avery W.
    Perl, Alexander E.
    Gill, Saar
    Babushok, Daria, V
    Hexner, Elizabeth O.
    Frey, Noelle, V
    Lai, Catherine
    Bruno, Ximena Jordan
    Martin, Mary Ellen
    Maillard, Ivan
    Porter, David L.
    Loren, Alison W.
    Pratz, Keith W.
    Luger, Selina M.
    Gimotty, Phyllis A.
    McCurdy, Shannon R.
    BLOOD, 2022, 140 : 10825 - 10827
  • [36] Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Yang, Rui
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Konopleva, Marina
    Faderl, Stefan
    Cortes, Jorge E.
    Brandt, Mark
    Hu, Yumin
    McCue, Deborah
    Newsome, Willie Mae
    Pierce, Sherry
    DeLima, Marcos
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 346 - 347
  • [37] Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Verstovsek, S
    Beran, M
    Andreeff, M
    Cortes, J
    Thomas, D
    Koller, C
    Pierce, S
    Ouzonian, S
    Kantarjian, H
    Estey, E
    BLOOD, 2002, 100 (11) : 342A - 342A
  • [38] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    BLOOD, 2014, 124 (21)
  • [39] Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.
    Ravandi, F.
    Faderl, S.
    Cortes, J. E.
    Garcia-Manero, G.
    Jabbour, E.
    Boone, P. A.
    Kadia, T. M.
    Borthakur, G.
    Wierda, W. G.
    Chiao, J. H.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] CONCOMITANT MONOCLONAL GAMMOPATHY OF UNKNOWN SIGNIFICANCE (MGUS) IN NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA (MDS/AML)
    Chen, Mingyi
    La, Hanh
    Abedi, Mehrdad
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2014, 36 : 47 - 48
12345